Nano and microtechnologies for the delivery of oligonucleotides with gene silencing properties.
Oligonucleotides (ONs) are synthetic fragments of nucleic acid designed to modulate the expression of target proteins. DNA-based ONs (antisense, antigene, aptamer or decoy) and more recently a new class of RNA-based ONs, the small interfering RNAs (siRNAs), have gained great attention for the treatment of different disease states, such as viral infections, inflammation, diabetes, and cancer. However, the development of therapeutic strategies based on ONs is hampered by their low bioavailability, poor intracellular uptake and rapid degradation in biological fluids. The use of a non-viral carrier can be a powerful tool to overcome these drawbacks. Lipid or polymer-based nanotechnologies can improve biological stability and cellular uptake of ONs, with possibility of tissue and/or cellular targeting. The use of polymeric devices can also produce a prolonged release of the ON, thus reducing the need of frequent administrations. This review summarizes advantages and issues related to the main non-viral vectors used for ON delivery.
De Rosa
Giuseppe
G
Dipartimento di Chimica Farmaceutica e Tossicologica, Facoltà di Farmacia, Università degli Studi di Napoli Federico II, Via D. Montesano 49, 80131 Naples, Italy. gderosa@unina.it
La Rotonda
Maria Immacolata
MI
D020868:Gene Silencing; D008081:Liposomes / Q000737:chemistry; D055616:Microtechnology / Q000379:methods*; D036103:Nanotechnology / Q000379:methods*; D009841:Oligonucleotides / Q000737:chemistry* / Q000235:genetics; D011108:Polymers / Q000737:chemistry; D034741:RNA, Small Interfering / Q000737:chemistry / Q000235:genetics
D008081:Liposomes; D009841:Oligonucleotides; D011108:Polymers; D034741:RNA, Small Interfering
AAPS PharmSciTech. 2008;9(2):335-41
18431646
Oligonucleotides. 2009 Jun;19(2):163-8
19441893
Biomacromolecules. 2006 Jan;7(1):347-56
16398535
Biochem Biophys Res Commun. 2005 May 13;330(3):755-9
15809061
Curr Med Chem. 2004 Jan;11(2):179-97
14754416
Biochemistry. 1993 May 11;32(18):4855-61
8490026
Genes Dev. 2001 Jan 15;15(2):188-200
11157775
Biomaterials. 2007 Feb;28(6):1280-8
17126901
Biochim Biophys Acta. 1996 Jun 11;1281(2):139-49
8664312
Mol Ther. 2006 Apr;13(4):644-70
16481219
Brain Dev. 2008 May;30(5):313-20
18358657
J Gene Med. 2005 Jun;7(6):771-81
15702489
Nature. 2000 Mar 16;404(6775):293-6
10749213
J Control Release. 2000 Oct 3;69(1):197-207
11018557
J Nanosci Nanotechnol. 2007 Nov;7(11):3695-9
18047039
Genes Dev. 1999 Dec 15;13(24):3191-7
10617568
Arthritis Rheum. 2006 Jun;54(6):1867-77
16729293
J Gene Med. 2009 Mar;11(3):229-39
19189285
Bioconjug Chem. 2003 May-Jun;14(3):672-8
12757394
Biochim Biophys Acta. 1994 Oct 12;1195(1):115-23
7918553
Mol Pharm. 2009 May-Jun;6(3):659-68
19267452
Biochim Biophys Acta. 2001 Feb 9;1510(1-2):152-66
11342155
Bioconjug Chem. 1999 Nov-Dec;10(6):1068-74
10563777
Nature. 2006 Jan 5;439(7072):89-94
16306938
Nat Rev Drug Discov. 2004 Dec;3(12):1023-35
15573101
Eur J Pharm Biopharm. 1999 Mar;47(2):119-23
10234535
Biomaterials. 1994 Dec;15(15):1209-13
7703316
Int J Pharm. 2007 Feb 1;329(1-2):1-11
17137734
J Control Release. 2006 May 15;112(2):257-70
16574264
Biochimie. 2007 Oct;89(10):1245-51
17619075
Clin Cancer Res. 2006 Feb 15;12(4):1251-9
16489081
J Control Release. 2006 Oct 10;115(2):216-25
16959358
J Biochem. 2001 May;129(5):755-9
11328598
Drug Deliv. 2002 Jul-Sep;9(3):169-80
12396734
Ann N Y Acad Sci. 2006 Oct;1082:1-8
17145918
Antisense Nucleic Acid Drug Dev. 2000 Oct;10(5):369-80
11079576
Gene Ther. 2005 Mar;12(5):461-6
15616603
Drug Metab Dispos. 2004 Sep;32(9):983-92
15319340
Bioconjug Chem. 2007 Mar-Apr;18(2):456-68
17326672
Mol Ther. 2009 Jul;17(7):1225-33
19401674
Pharm Res. 2008 Dec;25(12):2972-82
18709489
Bioconjug Chem. 1998 Nov-Dec;9(6):805-12
9815175
Int J Pharm. 2003 Mar 18;254(1):89-93
12615416
Mol Ther. 2009 Jan;17(1):162-8
18827803
Bioconjug Chem. 2004 Jul-Aug;15(4):677-84
15264853
Proc Natl Acad Sci U S A. 1998 Nov 10;95(23):13859-64
9811891
J Pharm Pharmacol. 2001 Aug;53(8):1047-67
11518015
Pharm Res. 2006 Apr;23(4):770-81
16572352
Proc Natl Acad Sci U S A. 2007 Apr 3;104(14):5715-21
17379663
Int J Pharm. 2007 Mar 1;331(2):167-75
17134859
Nat Biotechnol. 2005 Aug;23(8):1002-7
16041363
Surg Today. 2007;37(7):575-83
17593477
Biomaterials. 2007 Mar;28(7):1434-42
17141864
Mol Microbiol. 1992 Nov;6(22):3343-53
1484489
J Drug Target. 1998;5(4):291-302
9713978
Biochem Biophys Res Commun. 1993 Dec 15;197(2):818-25
8267621
Drug Discov Today. 2006 Jan;11(1-2):67-73
16478693
Biomacromolecules. 2003 May-Jun;4(3):529-36
12741766
Bioconjug Chem. 2005 Jul-Aug;16(4):986-94
16029041
Bioconjug Chem. 2003 Nov-Dec;14(6):1122-32
14624625
Proc Natl Acad Sci U S A. 1999 Apr 27;96(9):5177-81
10220439
Biomaterials. 2007 Aug;28(22):3360-8
17459468
Crit Rev Ther Drug Carrier Syst. 2005;22(6):535-602
16566705
Nature. 2006 May 4;441(7089):111-4
16565705
Biochim Biophys Acta. 1992 Aug 14;1113(2):201-27
1510997
Proc Natl Acad Sci U S A. 1995 Aug 1;92(16):7297-301
7638184
Bioconjug Chem. 2001 Mar-Apr;12(2):280-90
11312690
Biochemistry. 2007 Apr 24;46(16):4785-92
17391006
Genet Vaccines Ther. 2008 Feb 15;6:7
18279512
J Drug Target. 1998;5(3):149-62
9606005
J Control Release. 2002 Dec 5;84(3):171-81
12468220
Bioconjug Chem. 2006 Sep-Oct;17(5):1209-18
16984130
J Control Release. 2006 May 30;112(3):369-81
16644054
Eur J Pharm Biopharm. 2000 Jul;50(1):101-19
10840195
Hum Gene Ther. 2008 Aug;19(8):795-806
18647087
Int J Biochem Cell Biol. 2003 Jan;35(1):22-31
12467644
Hum Gene Ther. 2006 Jan;17(1):117-24
16409130
Mol Pharm. 2006 Sep-Oct;3(5):579-88
17009857
Nature. 1998 Feb 19;391(6669):806-11
9486653
J Control Release. 2000 Nov 3;69(2):309-22
11064137
Biochim Biophys Acta. 1994 Dec 30;1196(2):201-8
7841184
Bioconjug Chem. 2003 Jan-Feb;14(1):247-54
12526715
Curr Drug Targets. 2003 Nov;4(8):599-602
14577648
J Control Release. 2008 Mar 20;126(3):274-80
18237815
Biomaterials. 2008 Feb;29(4):506-12
17950838
Gene Ther. 2002 Dec;9(23):1607-16
12424613
J Drug Target. 2000;8(5):319-34
11328659
Cancer Gene Ther. 2001 Jun;8(6):459-68
11498766
Biomacromolecules. 2007 Apr;8(4):1333-40
17358077
Bioconjug Chem. 2003 Jan-Feb;14(1):255-61
12526716
Med Chem. 2005 Mar;1(2):199-208
16787315
Mol Pharmacol. 1992 Jun;41(6):1023-33
1352033
Clin Cancer Res. 2004 Nov 1;10(21):7244-51
15534098
Hum Gene Ther. 2005 Nov;16(11):1307-17
16259564
J Pharm Sci. 2002 Mar;91(3):790-9
11920765
J Pharm Pharmacol. 2003 Sep;55(9):1199-206
14604462
J Biomed Mater Res A. 2008 Mar 1;84(3):777-84
17635017
Pharm Res. 2006 Aug;23(8):1868-76
16845585
Mol Ther. 2006 Oct;14(4):476-84
16829204
Prostate. 2008 Sep 15;68(13):1430-42
18615483
Eur J Pharm Biopharm. 2008 Sep;70(1):7-18
18482831
Am J Physiol Gastrointest Liver Physiol. 2007 Sep;293(3):G631-9
17640975
Proc Natl Acad Sci U S A. 2007 Sep 25;104(39):15549-54
17875985
Biosci Rep. 1995 Feb;15(1):47-53
7647291
Trends Biotechnol. 1990 Dec;8(12):340-4
1366894
Curr Med Chem. 2005;12(19):2193-214
16178780
J Control Release. 1999 Aug 5;60(2-3):149-60
10425321
Proc Natl Acad Sci U S A. 1996 Oct 15;93(21):11493-8
8876163
J Mol Biol. 2003 Apr 4;327(4):761-6
12654261
Eur J Pharm Biopharm. 2004 May;57(3):427-30
15093589
Nucleic Acids Res. 1998 Apr 15;26(8):2016-23
9518498
J Control Release. 2008 Oct 6;131(1):64-9
18674578
J Biomed Mater Res. 1997 Jun 15;35(4):525-30
9189830
Biophys J. 2004 Jul;87(1):609-14
15240493
J Drug Target. 2003;11(8-10):495-507
15203918
Pharmacol Res. 2009 Jul;60(1):33-40
19427583
Antisense Nucleic Acid Drug Dev. 1999 Oct;9(5):451-8
10555152
J Nanobiotechnology. 2009 Apr 07;7:1
19351396
Biochim Biophys Acta. 1998 Feb 16;1390(2):119-33
9507083
Pharm Res. 1998 Sep;15(9):1326-31
9755881
Mol Pharm. 2009 May-Jun;6(3):727-37
19178144
Eur J Pharm Sci. 2000 May;10(3):187-93
10767596
Pharm Res. 1996 Sep;13(9):1367-72
8893276
J Control Release. 2006 Nov 28;116(2):179-91
16891028
Bioconjug Chem. 2002 May-Jun;13(3):630-9
12009955
Science. 1990 Nov 16;250(4983):997-1000
2237444
Eur J Pharm Biopharm. 2005 Aug;60(3):327-34
15894474